Drug development in Alzheimer's disease: the path to 2025 - Test2 - elhamkhani - TriplyDB

Drug development in Alzheimer's disease: the path to 2025

Drug development in Alzheimer's disease: the path to 2025

http://www.wikidata.org/entity/Q27007748

about

Oxidative Stress, Synaptic Dysfunction, and Alzheimer's Disease.Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease.Comparative study of therapeutic antibody candidates derived from mini-pool and clonal cell lines.Calcium signaling and molecular mechanisms underlying neurodegenerative diseases.RNA-binding proteins with prion-like domains in health and disease.Alzheimer's Disease in the Latino Community: Intersection of Genetics and Social Determinants of Health.A modified formulation of Huanglian-Jie-Du-Tang reduces memory impairments and β-amyloid plaques in a triple transgenic mouse model of Alzheimer's disease On the path to 2025: understanding the Alzheimer's disease continuum.Otophylloside B Protects Against Aβ Toxicity in Caenorhabditis elegans Models of Alzheimer's Disease.Alzheimer's disease drug development pipeline: 2017.Rebalancing β-Amyloid-Induced Decrease of ATP Level by Amorphous Nano/Micro Polyphosphate: Suppression of the Neurotoxic Effect of Amyloid β-Protein Fragment 25-35.Computer-Aided Drug Design Applied to Marine Drug Discovery: Meridianins as Alzheimer's Disease Therapeutic Agents.Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.Amylin in Alzheimer's disease: Pathological peptide or potential treatment?Combining in vitro and in silico approaches to find new drugs targeting the pathological proteins related to the Alzheimer's disease.β-Amyloid and the Pathomechanisms of Alzheimer's Disease: A Comprehensive View.β-Sheet Breaker Peptide-HPYD for the Treatment of Alzheimer's Disease: Primary Studies on Behavioral Test and Transcriptional Profiling.Prevention of Alzheimer's Disease: Lessons Learned and Applied.MH84 improves mitochondrial dysfunction in a mouse model of early Alzheimer's disease.Alzheimer's disease hypothesis and related therapies.Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs.A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025.Diagnosis of Alzheimer's disease with Electroencephalography in a differential framework.The Quest for an Alzheimer Therapy.Novel recruitment models will drive Alzheimer's trial success.[Drug treatment of dementia].Computer-Aided Multi-Target Management of Emergent Alzheimer's Disease.Human neural stem cell transplantation improves cognition in a murine model of Alzheimer's disease Therapeutic effect of Rho kinase inhibitor FSD-C10 in a mouse model of Alzheimer's disease Inflammation as a central mechanism in Alzheimer's disease Nuclear factor-kappa B: Glucocorticoid-induced leucine zipper interface analogs suppress pathology in an Alzheimer's disease model Cognitive composite score association with Alzheimer's disease plaque and tangle pathology Study partners: essential collaborators in discovering treatments for Alzheimer's disease

P2860

Q33614523-13ABDFC0-60B0-43CC-9997-5B0DEB3663BB Q33708963-FBEC9219-88BA-4B4E-A875-9C2B3786EF38 Q38557922-B5664210-6307-47AA-858D-87474CA3FA17 Q39152527-516CECAC-BFB2-4ED8-80F9-CC6BCF8478DD Q39227676-1569D778-5293-44EE-9DD2-ACED4E04FCA0 Q39319436-7786F0F3-77D6-4E64-860A-6ED61FA3C4C4 Q41109313-673FF71D-07EE-4809-8CDC-B35746911677 Q41318515-219AD4B8-B008-43BD-AF11-9E1716C917B8 Q41911575-E2622723-1315-4F9E-810C-3E445B0E1450 Q42655757-72C770A6-4DB1-4F02-B8F3-47E0027E37CB Q43227037-A418D8B6-AC1A-4F54-97A4-5C47F75A31AF Q46251798-25F322F2-2C10-4C03-B5F2-C19FD54C7CE6 Q46254853-B55831A1-85A4-4F64-A1CB-09E143A9292D Q47322028-4E57C630-DC62-47E9-80D5-CCCD6A1226E8 Q47396500-C858693A-20AA-48B8-AA73-4DAAD994861F Q47672665-36C95ACD-153F-467C-8729-2CCD95073930 Q47705574-28739555-3257-45A9-A4B3-E471B2625C71 Q48169850-DABD25F4-483C-4B43-BFDE-D2FE22BA983D Q49491716-C8187C55-2304-4CFE-95FD-6034A48F71CD Q49762112-E75627A3-AE04-40ED-8E17-810A83785691 Q50326656-E66CBF25-C376-49F3-8A80-A4481F664EEA Q51749122-0FBE11C2-1666-4C86-A3BB-DAC06DC2147F Q51761233-F9C3B4AF-83EA-49F6-9DA9-96C48755F84A Q52620591-274867BD-D3AA-44C6-BB31-EDD4820C4B77 Q52777452-50DECB71-BF78-46A9-BD60-812BB745E2C0 Q53675854-77CEBD85-3FB8-4861-A4A3-6EFB9D4AA50C Q55456183-3267B4DB-D8AB-44AF-A9D2-2CA88230875F Q57041817-CED99958-9BD5-4C62-9975-5BD0E6896742 Q57787052-A524CA8E-339A-4338-95DF-F86922E6908A Q58555818-5CE7FCE1-9CC8-45EF-8E0D-AA4C1082F66A Q58574209-3017E1CC-6F69-4A44-A515-EA3DE40D1AD1 Q58751300-F00D0508-4905-4E3C-82A8-D32C84AAA2F6 Q59128442-192506A2-ADFD-4632-BCC7-46F9A98BEDAF

P2860

Drug development in Alzheimer's disease: the path to 2025

http://www.wikidata.org/entity/Q27007748

description

2016 nî lūn-bûn

@nan

2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Drug development in Alzheimer's disease: the path to 2025

@ast

Drug development in Alzheimer's disease: the path to 2025

@en

Drug development in Alzheimer's disease: the path to 2025

@nl

type

label

Drug development in Alzheimer's disease: the path to 2025

@ast

Drug development in Alzheimer's disease: the path to 2025

@en

Drug development in Alzheimer's disease: the path to 2025

@nl

prefLabel

Drug development in Alzheimer's disease: the path to 2025

@ast

Drug development in Alzheimer's disease: the path to 2025

@en

Drug development in Alzheimer's disease: the path to 2025

@nl

P1433

Q27007748-58B62FB5-527A-4EBE-8EDE-A8AD77E286FE

P1476

Q27007748-891BE919-B4F4-4D34-8674-1042644F34D2

P2093

Q27007748-1EC68972-E966-4A66-AD0F-296BEE06651B

Q27007748-348C0C2F-E39B-4472-9636-5FF07DDF1F5F

Q27007748-594BC9D0-77AD-4FEF-86B4-C2ED5F4413E7

Q27007748-E88ED491-98C6-46DE-9F1A-1B3BA73794A2

Q27007748-ECC7154F-188F-4BC8-9283-9926D0372D12

P275

Q27007748-1356842A-1048-4B1B-9048-8D7B190AF4E5

P2860

Q27007748-04455502-7CA8-452E-A1A8-A1C658EBE68D

Q27007748-045F7F11-7898-4A36-B051-B487F1236988

Q27007748-0F4BF910-7DCC-49E4-960F-DB0198F78ABD

Q27007748-157B933B-9BF0-444A-8716-ED451A78D4A4

Q27007748-16DEB013-B69F-4601-B60D-93974BE30148

Q27007748-1C9A61B0-BCD3-4C75-89F1-B369DFF1CEE3

Q27007748-24FAB1B6-11A3-4826-92EC-040A5DE5CE84

Q27007748-25990A88-480B-4942-9032-A2CE0AA4CC7C

Q27007748-2922260A-DA08-402E-A8C3-A0757C2D7F05

Q27007748-2FCC9157-38D3-48D8-B37C-FDACBEFFA884

P2888

Q27007748-B5A4F938-555F-40E1-9134-7AB11896991F

P304

Q27007748-219E76C5-630A-4CFB-8E04-A22204E8B3EF

P31

Q27007748-8B8C462E-6568-47E6-A0DE-29B98492F066

Q27007748-A506B3FB-2599-4AE8-BAA6-4B8CA3757ED5

P3181

Q27007748-7F5F954D-D246-4D61-9BF6-88F48963769F

P356

Q27007748-71D4B9C6-F7ED-4097-8640-ED4E8F6E6FCD

P407

Q27007748-9A4C15BB-8D0F-4670-AAD9-DA1390F13374

P433

Q27007748-4E6083D9-3269-4824-B5A4-8B25C5352B58

P478

Q27007748-8309D88D-FE2C-471C-A5ED-090642B47161

P50

Q27007748-1C74C95E-89BB-412D-B629-EE3D3E1F1A77

Q27007748-1C9F6C2D-173F-4A77-BD54-26FB41B219BE

Q27007748-3609A04E-D51F-40AC-9DE8-88C0F72EDB10

Q27007748-625C126B-A2CB-4D63-9F4F-E73DE36292AC

Q27007748-9CF666F7-B144-430A-B291-9DD3B7738507

P5008

Q27007748-F5F0D5E7-B37A-47D9-AD28-00C6E7041E4B

P577

Q27007748-F5C9B790-2659-4835-95E6-BAB2588DC7D0

P6179

Q27007748-E6E8A54F-55C5-4F3F-8540-AC8AFA5B71E8

P698

Q27007748-27A270E9-3F8C-48E1-8514-3ED6B641CB7C

P921

Q27007748-5776700F-CCDF-479E-856C-81E7288EEDE7

Q27007748-5C6DBC35-4267-41E1-BBAE-368C2FFBEE10

Q27007748-AECC6AE2-46DD-4B3C-8071-E824B97BB7A5

P932

Q27007748-96BB2D27-0DF7-4C73-A6CC-F940158DA411

P3181

P356

S13195-016-0207-9

P1433

Alzheimers Research & Therapy

P1476

Drug development in Alzheimer's disease: the path to 2025

@en

P2093

Bruno DuBois

http://www.w3.org/2001/XMLSchema#string

Joel Raskin

http://www.w3.org/2001/XMLSchema#string

Lutz Frölich

http://www.w3.org/2001/XMLSchema#string

Roy W Jones

http://www.w3.org/2001/XMLSchema#string

Sherie A Dowsett

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer's disease model.

Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation

Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

Alzheimer's disease.

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

Alzheimer's disease drug-development pipeline: few candidates, frequent failures

Amnestic MCI or prodromal Alzheimer's disease?

Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline

P2888

s13195-016-0207-9

P304

39

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3458982

http://www.w3.org/2001/XMLSchema#string

P356

10.1186/S13195-016-0207-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

Philip Scheltens

Jeffrey L. Cummings

P5008

P577

2016-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1027076348

http://www.w3.org/2001/XMLSchema#string

P698

27646601

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

biomedical investigative technique

P932

5028936

http://www.w3.org/2001/XMLSchema#string